Ascendis officer plans 3,000-ADS Rule 144 sale

An Ascendis Pharma A/S officer plans a Rule 144 sale of 3,000 ADSs after a cash warrant exercise through Merrill Lynch.

Available on EDGAR 09/08/2026 - 04:17 PM EDT Accepted by SEC EDGAR 09/08/2026 - 04:16 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Ascendis Pharma A/S (ASND) has a notice filed on behalf of officer Mads Bodenhoff to sell Ascendis American Depositary Shares under Rule 144. The planned sale covers 3,000 American Depositary Shares, with an stated aggregate market value of 810,562.66, to be effected through Merrill Lynch on or after September 8, 2026 following a warrant exercise for cash.

Key Figures

ADSs planned for sale: 3,000 American Depositary Shares Aggregate market value: 810,562.66 Planned sale date: September 8, 2026

3 metrics

ADSs planned for sale 3,000 American Depositary Shares Number of Ascendis Pharma A/S ADSs covered by the Rule 144 notice

Aggregate market value 810,562.66 Aggregate market value of the 3,000 ADSs to be sold

Planned sale date September 8, 2026 Date listed for sale of ADSs on NASDAQ

Key Terms

Rule 144, American Depositary Shares, Warrant exercise

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

American Depositary Shares financial

"American Depositary Shares | Merrill Lynch 225 Liberty Street Floor 37"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Warrant exercise financial

"American Depositary Shares | 09/08/2026 | Warrant exercise | Ascendis Pharma A/S"

A warrant exercise is when the holder of a warrant pays a preset price to convert that warrant into actual company shares. Think of it like using a coupon to buy a product at a locked-in price; if the market price is higher, the buyer gains immediate value. For investors it matters because exercising brings cash into the company but also increases the total number of shares, which can reduce each existing shareholder’s ownership percentage and affect the stock price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 notice disclose for Ascendis Pharma (ASND)?

The notice states that officer Mads Bodenhoff intends to sell 3,000 American Depositary Shares of Ascendis Pharma A/S under Rule 144, with the planned sale through Merrill Lynch after a warrant exercise for cash on or after September 8, 2026.

How many Ascendis Pharma (ASND) shares are covered by this Form 144?

The Form 144 covers 3,000 American Depositary Shares of Ascendis Pharma A/S. These shares are planned to be sold following a warrant exercise for cash and are to be traded on NASDAQ through Merrill Lynch.

What is the aggregate market value of ASND shares in this planned Rule 144 sale?

The filing lists an aggregate market value of 810,562.66 for the 3,000 American Depositary Shares of Ascendis Pharma A/S that are intended to be sold under Rule 144.

When is the planned sale date for the Ascendis Pharma (ASND) ADSs?

The document indicates a planned sale date of September 8, 2026 for the 3,000 American Depositary Shares of Ascendis Pharma A/S to be sold under Rule 144 on NASDAQ.

How will the Ascendis Pharma (ASND) shares be acquired before sale?

The 3,000 American Depositary Shares of Ascendis Pharma A/S are to be acquired via a warrant exercise for cash on September 8, 2026, with those shares then eligible for sale under Rule 144.

Which broker is involved in the Ascendis Pharma (ASND) Form 144 transaction?

The Form 144 identifies Merrill Lynch, located at 225 Liberty Street in New York, as the broker handling the planned sale of 3,000 American Depositary Shares of Ascendis Pharma A/S on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002014697
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Ascendis Pharma A/S
SEC File Number	001-36815
Address of Issuer	TUBORG BOULEVARD 12 HELLERUP DENMARK 00000
Phone	45 70 22 22 44
Name of Person for Whose Account the Securities are To Be Sold	Bodenhoff Mads
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	3000	810562.66	66189926	09/08/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
American Depositary Shares	09/08/2026	Warrant exercise	Ascendis Pharma A/S			3000	09/08/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/08/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Mads Bodenhoff
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)